Holen Sie sich die Stockscreener-App
24.88
1.39%
0.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.54
Offen:
$24.57
24-Stunden-Volumen:
34.57M
Relative Volume:
0.87
Marktkapitalisierung:
$141.46B
Einnahmen:
$63.83B
Nettoeinkommen (Verlust:
$10.77B
KGV:
13.23
EPS:
1.88
Netto-Cashflow:
$12.44B
1W Leistung:
+0.48%
1M Leistung:
+0.53%
6M Leistung:
-4.09%
1J Leistung:
-12.73%
1-Tages-Spanne:
$24.50
$24.89
1-Wochen-Bereich:
$24.35
$25.12
52-Wochen-Spanne:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.88 | 139.52B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
727.21 | 665.99B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.43 | 430.51B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
212.56 | 376.28B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
129.73 | 248.60B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.71 | 209.94B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time. - The Motley Fool
Pfizer Inc (PFE) Announces New Trial Collaboration With Olema Pharmaceuticals - MSN
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
2nd Circ. Backs Ex-Pfizer Worker's Insider Trading Conviction - Law360
Vitiligo Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotech - Barchart.com
Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks (NYSE:PFE) - Seeking Alpha
Pfizer and BioNTech: Slightly Lowering Our MRNA Vaccine Forecast Due to US Policy Headwinds - Morningstar
Alopecia Market Key Players AnalysisPfizer, Inc., Lilly, Lexington Intl., LLC, Freedom Laser Therapy, Curallux. - openPR.com
Is Pfizer Inc. reversing from oversold territoryWeekly Profit Recap & Verified Technical Trade Signals - Newser
Pfizer's Diverse Portfolio Supports a Narrow Moat, Despite Patent Loss Headwinds - Morningstar
Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - sharewise.com
Is Pfizer Inc. backed by strong institutional buying2025 Risk Factors & Weekly High Return Forecasts - خودرو بانک
Is Pfizer Stock A Sell On Its Severely Limited Covid Shots? - Investor's Business Daily
Pfizer Inc. (NYSE:PFE) Q1 2025 Earnings Call Transcript - MSN
B-cell Lymphoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Biegene, Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc - Barchart.com
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (September 2025) - 24/7 Wall St.
Type 1 Diabetes Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer - Barchart.com
Antimicrobial Therapeutics Market to Witness Massive Growth - openPR.com
3 Things You Need to Know if You Buy Pfizer Today - The Globe and Mail
Stock Analysis | Pfizer OutlookNavigating Volatility Amid Mixed Signals - AInvest
Global Vaccines Market is expected to reach US$ 108.82 billion - openPR.com
Eye Health Supplements Market Rocketing by 2032 with Industry - openPR.com
Pfizer CEO is latest to say Trump should get Nobel Peace Prize – for something much of MAGA hates - AOL.com
Cassidy, Pfizer CEO: Trump worthy of Nobel prize for COVID vaccine - AOL.com
Pfizer collaboration with Olema may spark future bidding waranalyst - MSN
Trump "worthy of the Nobel Peace Prize" for COVID vaccines, Pfizer CEO says - Axios
Pfizer, Moderna, Novavax respond to Trump’s criticism of COVID shot success - Seeking Alpha
Pfizer, Moderna defend COVID vaccine effectiveness after Trump remarks - Reuters
Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Phar - Barchart.com
Pfizer responds to Trump’s call for Covid-19 vaccine data, says Operation Warp Speed deserves Nobel Peace Prize - News Channel 3-12
Pfizer defends COVID-19 vaccine effectiveness after Trump remarks - Reuters
Updated: Responding to Trump, Pfizer CEO Bourla stands by Covid-19 vaccine data - Endpoints News
Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study - simplywall.st
Pfizer Reaffirms Transparency Commitment On COVID-19 Vaccine Data - Nasdaq
Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize - Yahoo Finance
Pfizer to Continue Disclosing Research Analysis of COVID-19 Vaccine; Calls Operation Warp Speed 'Success' - MarketScreener
Pfizer Defends Covid Vaccine Transparency in Response to Trump - Bloomberg
Pfizer defends Covid-19 vaccine transparency in response to Trump - The Edge Malaysia
Pfizer reaffirms commitment to COVID-19 vaccine transparency - Investing.com
Pfizer : Responds to Success of Operation Warp Speed and Reaffirms Transparency of COVID Vaccine Data - MarketScreener
Pfizer says it will soon share new data on latest vaccine strain which FDA approved - MarketScreener
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Pfizer (PFE) Volatility and Risk Allocation: Navigating a Shifting Pharmaceutical Landscape - AInvest
Pfizer's Strategic Reinvention: Execution Discipline and Risk Allocation Reshape Valuation Narrative - AInvest
What are Pfizer Inc.’s earnings expectationsMarket Performance Report & Low Drawdown Investment Ideas - خودرو بانک
Pfizer's Strategic Volatility: Tactical Entry Points and Rule-Based Trading in a Biotech Recovery - AInvest
Pfizer's Strategic Volatility: Decoding Recent Share Price Swings and Tactical Entry Points - AInvest
Growth Report: Is Pfizer Inc. attractive at current valuationWeekly Investment Recap & Risk Controlled Stock Alerts - خودرو بانک
Pfizer's Surging Momentum: A Catalyst for Large-Cap Biotech Growth - AInvest
$33M Pfizer Antitrust Deal OK'd, First MDL Trial Date Set - Law360
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
1.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):